Based on the Kronos Bio Inc stock forecast from 1 analysts, the average analyst target price for Kronos Bio Inc is USD 1.00 over the next 12 months. Kronos Bio Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Kronos Bio Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Kronos Bio Inc’s stock price was USD 0.91. Kronos Bio Inc’s stock price has changed by +5.53% over the past week, +3.95% over the past month and -10.40% over the last year.
No recent analyst target price found for Kronos Bio Inc
No recent average analyst rating found for Kronos Bio Inc
Company Overview Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. Read Less
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the ...Read More
Frequently Asked Questions About Kronos Bio Inc (KRON) Stock
Based on ratings from 1 analysts Kronos Bio Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on KRON's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for KRON is USD 1.00 over the next 12 months. The maximum analyst target price is USD 1 while the minimum anlayst target price is USD 1.
Unfortunately we do not have enough data on KRON's stock to indicate if its overvalued.
The last closing price of KRON's stock was USD 0.91.
The most recent market capitalization for KRON is USD 0.05B.
Based on targets from 1 analysts, the average taret price for KRON is projected at USD 1.00 over the next 12 months.
This means that KRON's stock price may go up by +10.50% over the next 12 months.
We can't find any ETFs which contains Kronos Bio Inc's stock.
As per our most recent records Kronos Bio Inc has 10 Employees.
Kronos Bio Inc's registered address is 1300 So. El Camino Real, San Mateo, CA, United States, 94402.
You can get more information about it from Kronos Bio Inc's website at https://www.kronosbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Kronos Bio Inc (KRON) Stock
Based on ratings from 1 analysts Kronos Bio Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on KRON's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for KRON is USD 1.00 over the next 12 months. The maximum analyst target price is USD 1 while the minimum anlayst target price is USD 1.
Unfortunately we do not have enough data on KRON's stock to indicate if its overvalued.
The last closing price of KRON's stock was USD 0.91.
The most recent market capitalization for KRON is USD 0.05B.
Based on targets from 1 analysts, the average taret price for KRON is projected at USD 1.00 over the next 12 months.
This means that KRON's stock price may go up by +10.50% over the next 12 months.
We can't find any ETFs which contains Kronos Bio Inc's stock.
As per our most recent records Kronos Bio Inc has 10 Employees.
Kronos Bio Inc's registered address is 1300 So. El Camino Real, San Mateo, CA, United States, 94402.
You can get more information about it from Kronos Bio Inc's website at https://www.kronosbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for KRON !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
